NEU3 and idiopathic pulmonary fibrosis: The observation that the upregulated NEU3 in IPF desialylates and inactivates SAP suggests that our new class of NEU3 inhibitors could be useful as stand-alone therapeutics, or therapeutics to bolster the efficacy of SAP.